Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2 | Zendy

Henry Pertinez | Zendy; Rajith K. R. Rajoli | Zendy; Saye Khoo | Zendy; Andrew Owen | Zendy

Open Access

Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

Author(s) -

Henry Pertinez,

Rajith K. R. Rajoli,

Saye Khoo,

Andrew Owen

Publication year - 2021

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkab135

Subject(s) - intracellular , pharmacokinetics , favipiravir , pharmacology , population , chemistry , loading dose , medicine , biochemistry , covid-19 , disease , environmental health , infectious disease (medical specialty)

Favipiravir has discrepant activity against SARS-CoV-2 in vitro, concerns about teratogenicity and pill burden, and an unknown optimal dose. This analysis used available data to simulate the intracellular pharmacokinetics of the favipiravir active metabolite [favipiravir ribofuranosyl-5'-triphosphate (FAVI-RTP)].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research